Macitentan and phosphodiesterase-5 inhibitor alone or in combination in newly diagnosed pulmonary arterial hypertension: a pooled analysis

INTRODUCTION: Upfront combination therapy with endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE5i) is guideline-recommended for low- or intermediate-risk pulmonary arterial hypertension (PAH). This study compared time to all-cause mortality for macitentan+PDE5i combination...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Vallerie V. McLaughlin, MD, Nicolas Sauvageot, PhD, Brian Hennessy, PhD, Sumeet Panjabi, PhD, Carly J. Paoli, PharmD, MPH, Jörg Linder, PhD, Bjorn Bayer, MS, Stefan Söderberg, MD, PhD, Sean Gaine, MD, PhD, FRCPI, Tobias J. Lange, MD, Nick H. Kim, MD
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-02-01
coleção:	JHLT Open
Assuntos:	Pulmonary arterial hypertension Macitentan Phosphodiesterase-5 inhibitor Endothelin receptor antagonist Upfront combination therapy Mortality
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2950133425002617
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!